Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.
Identifieur interne : 000F27 ( Main/Exploration ); précédent : 000F26; suivant : 000F28Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.
Auteurs : Canan G. Nebigil [France] ; Christiane Moog [France] ; Stéphan Vagner [France] ; Nadia Benkirane-Jessel [France] ; Duncan R. Smith [Thaïlande] ; Laurent Désaubry [France]Source :
- European journal of medicinal chemistry [ 1768-3254 ] ; 2020.
Descripteurs français
- KwdFr :
- Aglaia (composition chimique), Animaux (MeSH), Antiviraux (usage thérapeutique), Facteur-4A d'initiation eucaryote (effets des médicaments et des substances chimiques), Facteur-4A d'initiation eucaryote (génétique), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Médecine traditionnelle chinoise (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Produits biologiques (usage thérapeutique), Protéines de répression (effets des médicaments et des substances chimiques), Protéines de répression (génétique).
- MESH :
- composition chimique : Aglaia.
- effets des médicaments et des substances chimiques : Facteur-4A d'initiation eucaryote, Protéines de répression.
- génétique : Facteur-4A d'initiation eucaryote, Protéines de répression.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Produits biologiques.
- Animaux, Humains, Médecine traditionnelle chinoise, Pandémies.
English descriptors
- KwdEn :
- Aglaia (chemistry), Animals (MeSH), Antiviral Agents (therapeutic use), Biological Products (therapeutic use), Coronavirus Infections (drug therapy), Eukaryotic Initiation Factor-4A (drug effects), Eukaryotic Initiation Factor-4A (genetics), Humans (MeSH), Medicine, Chinese Traditional (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Repressor Proteins (drug effects), Repressor Proteins (genetics).
- MESH :
- chemical , drug effects : Eukaryotic Initiation Factor-4A, Repressor Proteins.
- chemical , genetics : Eukaryotic Initiation Factor-4A, Repressor Proteins.
- chemical , therapeutic use : Antiviral Agents, Biological Products.
- chemistry : Aglaia.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Animals, Humans, Medicine, Chinese Traditional, Pandemics.
Abstract
Flavaglines are cyclopenta[b]benzofurans found in plants of the genus Aglaia, several species of which are used in traditional Chinese medicine. These compounds target the initiation factor of translation eIF4A and the scaffold proteins prohibitins-1 and 2 (PHB1/2) to exert various pharmacological activities, including antiviral effects against several types of viruses, including coronaviruses. This review is focused on the antiviral effects of flavaglines and their therapeutic potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
DOI: 10.1016/j.ejmech.2020.112653
PubMed: 32693294
PubMed Central: PMC7362831
Affiliations:
- France, Thaïlande
- Alsace (région administrative), Grand Est
- Orsay, Strasbourg
- Université de Strasbourg
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.</title><author><name sortKey="Nebigil, Canan G" sort="Nebigil, Canan G" uniqKey="Nebigil C" first="Canan G" last="Nebigil">Canan G. Nebigil</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Moog, Christiane" sort="Moog, Christiane" uniqKey="Moog C" first="Christiane" last="Moog">Christiane Moog</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Vagner, Stephan" sort="Vagner, Stephan" uniqKey="Vagner S" first="Stéphan" last="Vagner">Stéphan Vagner</name><affiliation wicri:level="3"><nlm:affiliation>Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France; Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3348, INSERM U1278, Orsay, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France; Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3348, INSERM U1278, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Benkirane Jessel, Nadia" sort="Benkirane Jessel, Nadia" uniqKey="Benkirane Jessel N" first="Nadia" last="Benkirane-Jessel">Nadia Benkirane-Jessel</name><affiliation wicri:level="4"><nlm:affiliation>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg, 8 Rue de Ste Elisabeth, 67000, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg, 8 Rue de Ste Elisabeth, 67000, Strasbourg</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName><orgName type="university">Université de Strasbourg</orgName></affiliation></author><author><name sortKey="Smith, Duncan R" sort="Smith, Duncan R" uniqKey="Smith D" first="Duncan R" last="Smith">Duncan R. Smith</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Institute of Molecular Biosciences, Mahidol University, Salaya, 73170</wicri:regionArea><wicri:noRegion>73170</wicri:noRegion></affiliation></author><author><name sortKey="Desaubry, Laurent" sort="Desaubry, Laurent" uniqKey="Desaubry L" first="Laurent" last="Désaubry">Laurent Désaubry</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France. Electronic address: desaubry@unistra.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32693294</idno><idno type="pmid">32693294</idno><idno type="doi">10.1016/j.ejmech.2020.112653</idno><idno type="pmc">PMC7362831</idno><idno type="wicri:Area/Main/Corpus">000883</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000883</idno><idno type="wicri:Area/Main/Curation">000883</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000883</idno><idno type="wicri:Area/Main/Exploration">000883</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.</title><author><name sortKey="Nebigil, Canan G" sort="Nebigil, Canan G" uniqKey="Nebigil C" first="Canan G" last="Nebigil">Canan G. Nebigil</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Moog, Christiane" sort="Moog, Christiane" uniqKey="Moog C" first="Christiane" last="Moog">Christiane Moog</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Vagner, Stephan" sort="Vagner, Stephan" uniqKey="Vagner S" first="Stéphan" last="Vagner">Stéphan Vagner</name><affiliation wicri:level="3"><nlm:affiliation>Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France; Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3348, INSERM U1278, Orsay, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France; Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3348, INSERM U1278, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Benkirane Jessel, Nadia" sort="Benkirane Jessel, Nadia" uniqKey="Benkirane Jessel N" first="Nadia" last="Benkirane-Jessel">Nadia Benkirane-Jessel</name><affiliation wicri:level="4"><nlm:affiliation>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg, 8 Rue de Ste Elisabeth, 67000, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg, 8 Rue de Ste Elisabeth, 67000, Strasbourg</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName><orgName type="university">Université de Strasbourg</orgName></affiliation></author><author><name sortKey="Smith, Duncan R" sort="Smith, Duncan R" uniqKey="Smith D" first="Duncan R" last="Smith">Duncan R. Smith</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Institute of Molecular Biosciences, Mahidol University, Salaya, 73170</wicri:regionArea><wicri:noRegion>73170</wicri:noRegion></affiliation></author><author><name sortKey="Desaubry, Laurent" sort="Desaubry, Laurent" uniqKey="Desaubry L" first="Laurent" last="Désaubry">Laurent Désaubry</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France. Electronic address: desaubry@unistra.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author></analytic><series><title level="j">European journal of medicinal chemistry</title><idno type="eISSN">1768-3254</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aglaia (chemistry)</term><term>Animals (MeSH)</term><term>Antiviral Agents (therapeutic use)</term><term>Biological Products (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Eukaryotic Initiation Factor-4A (drug effects)</term><term>Eukaryotic Initiation Factor-4A (genetics)</term><term>Humans (MeSH)</term><term>Medicine, Chinese Traditional (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Repressor Proteins (drug effects)</term><term>Repressor Proteins (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Aglaia (composition chimique)</term><term>Animaux (MeSH)</term><term>Antiviraux (usage thérapeutique)</term><term>Facteur-4A d'initiation eucaryote (effets des médicaments et des substances chimiques)</term><term>Facteur-4A d'initiation eucaryote (génétique)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Médecine traditionnelle chinoise (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Produits biologiques (usage thérapeutique)</term><term>Protéines de répression (effets des médicaments et des substances chimiques)</term><term>Protéines de répression (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Eukaryotic Initiation Factor-4A</term><term>Repressor Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Eukaryotic Initiation Factor-4A</term><term>Repressor Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Biological Products</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Aglaia</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Aglaia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Facteur-4A d'initiation eucaryote</term><term>Protéines de répression</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Facteur-4A d'initiation eucaryote</term><term>Protéines de répression</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Produits biologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Medicine, Chinese Traditional</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Médecine traditionnelle chinoise</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Flavaglines are cyclopenta[b]benzofurans found in plants of the genus Aglaia, several species of which are used in traditional Chinese medicine. These compounds target the initiation factor of translation eIF4A and the scaffold proteins prohibitins-1 and 2 (PHB1/2) to exert various pharmacological activities, including antiviral effects against several types of viruses, including coronaviruses. This review is focused on the antiviral effects of flavaglines and their therapeutic potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32693294</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3254</ISSN><JournalIssue CitedMedium="Internet"><Volume>203</Volume><PubDate><Year>2020</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>European journal of medicinal chemistry</Title><ISOAbbreviation>Eur J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.</ArticleTitle><Pagination><MedlinePgn>112653</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0223-5234(20)30625-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2020.112653</ELocationID><Abstract><AbstractText>Flavaglines are cyclopenta[b]benzofurans found in plants of the genus Aglaia, several species of which are used in traditional Chinese medicine. These compounds target the initiation factor of translation eIF4A and the scaffold proteins prohibitins-1 and 2 (PHB1/2) to exert various pharmacological activities, including antiviral effects against several types of viruses, including coronaviruses. This review is focused on the antiviral effects of flavaglines and their therapeutic potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nebigil</LastName><ForeName>Canan G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moog</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vagner</LastName><ForeName>Stéphan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France; Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3348, INSERM U1278, Orsay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benkirane-Jessel</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg, 8 Rue de Ste Elisabeth, 67000, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Duncan R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Désaubry</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France. Electronic address: desaubry@unistra.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Med Chem</MedlineTA><NlmUniqueID>0420510</NlmUniqueID><ISSNLinking>0223-5234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000709175">EIF4A1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C067438">prohibitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D039601">Eukaryotic Initiation Factor-4A</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D031602" MajorTopicYN="N">Aglaia</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039601" MajorTopicYN="N">Eukaryotic Initiation Factor-4A</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chikungunya virus</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Ebola virus</Keyword><Keyword MajorTopicYN="N">Natural products</Keyword><Keyword MajorTopicYN="N">Picornaviruses</Keyword><Keyword MajorTopicYN="N">Prohibitin</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Zika virus</Keyword><Keyword MajorTopicYN="N">eIF4A</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32693294</ArticleId><ArticleId IdType="pii">S0223-5234(20)30625-5</ArticleId><ArticleId IdType="doi">10.1016/j.ejmech.2020.112653</ArticleId><ArticleId IdType="pmc">PMC7362831</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>Thaïlande</li></country><region><li>Alsace (région administrative)</li><li>Grand Est</li></region><settlement><li>Orsay</li><li>Strasbourg</li></settlement><orgName><li>Université de Strasbourg</li></orgName></list><tree><country name="France"><region name="Grand Est"><name sortKey="Nebigil, Canan G" sort="Nebigil, Canan G" uniqKey="Nebigil C" first="Canan G" last="Nebigil">Canan G. Nebigil</name></region><name sortKey="Benkirane Jessel, Nadia" sort="Benkirane Jessel, Nadia" uniqKey="Benkirane Jessel N" first="Nadia" last="Benkirane-Jessel">Nadia Benkirane-Jessel</name><name sortKey="Desaubry, Laurent" sort="Desaubry, Laurent" uniqKey="Desaubry L" first="Laurent" last="Désaubry">Laurent Désaubry</name><name sortKey="Moog, Christiane" sort="Moog, Christiane" uniqKey="Moog C" first="Christiane" last="Moog">Christiane Moog</name><name sortKey="Vagner, Stephan" sort="Vagner, Stephan" uniqKey="Vagner S" first="Stéphan" last="Vagner">Stéphan Vagner</name></country><country name="Thaïlande"><noRegion><name sortKey="Smith, Duncan R" sort="Smith, Duncan R" uniqKey="Smith D" first="Duncan R" last="Smith">Duncan R. Smith</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32693294
|texte= Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32693294" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |